Drug intelligence / Profile preview

JJGW07

Development stage: Preclinical
Modality: Small Molecules

Overview

JJGW07 is a novel arylpiperazine derivative of salicylamide. It acts as an antagonist at dopamine D2 and serotonin 5-HT1A receptors, and exhibits weak antagonistic properties at serotonin 5-HT2A and 5-HT7 receptors. JJGW07 shows antidepressant-like, anxiolytic-like, and antipsychotic-like effects in rodents, with anti-amnesic properties on long-term emotional memory. It does not impair motor coordination or induce catalepsy at antipsychotic-like doses.

Other names: Novel arylpiperazine derivative of salicylamide

Targets

HTR2A (Serotonin receptor 5-HT2A)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))DRD2 (Dopamine D2 Receptor)HTR7 (5-hydroxytryptamine receptor 7)

Beyond the preview

Go deeper on JJGW07.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JJGW07.

Explore the full profile